The Practice of Yoon Hang Kim, MD

Clinical Insights in Integrative & Functional Medicine

Thymosin Alpha-1 in Integrative Oncology: Mechanisms, Clinical Evidence, and Emerging Applications

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

The Practice of Yoon Hang Kim, MD

Abstract

Thymosin Alpha-1 (Tα1) is a 28-amino acid endogenous peptide produced by thymic epithelial cells with well-established immunomodulatory properties. Originally studied in the context of viral hepatitis and immune reconstitution, Tα1 has garnered increasing attention in oncology for its capacity to enhance T-cell function, promote dendritic cell maturation, reverse tumor-associated immunosuppression, and mitigate treatment-induced lymphopenia. This article provides a comprehensive academic review of the peer-reviewed literature on Tα1 in cancer, with a focus on mechanisms of action, tumor-type-specific clinical data, synergy with immune checkpoint inhibitors and radiotherapy, safety profile, and future research directions. Current evidence from PubMed-indexed studies supports Tα1 as a promising adjunctive immunomodulatory agent across multiple malignancies, including non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), melanoma, and breast cancer, though large-scale randomized controlled trials remain limited.

Keywords: thymosin alpha-1, thymalfasin, Tα1, cancer immunotherapy, tumor microenvironment, checkpoint inhibitors, lymphopenia, non-small cell lung cancer, hepatocellular carcinoma, integrative oncology, myeloid-derived suppressor cells, PD-1, dendritic cells

1. Introduction

The intersection of immunology and oncology has produced some of the most consequential therapeutic advances in modern medicine. Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1 (PD-1), its ligand (PD-L1), and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) have redefined the treatment landscape for melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and numerous other malignancies. Despite these advances, durable responses remain confined to a minority of patients, and treatment-related immune toxicities, treatment-induced lymphopenia, and immunosuppressive tumor microenvironments (TME) continue to limit efficacy (Solmonese et al., 2025).

Thymosin Alpha-1 (Tα1), commercially known as thymalfasin and trademarked as Zadaxin™, is a naturally occurring, acetylated 28-amino acid peptide derived from prothymosin-α, a protein encoded by the PTMA gene and produced primarily by thymic epithelial cells. First isolated and characterized in the 1970s by Allan Goldstein and colleagues, Tα1 plays a central role in T-cell maturation, differentiation, and immune homeostasis. Its synthetic form has been approved in over 35 countries for the adjunct treatment of chronic hepatitis B, chronic hepatitis C, and as a vaccine enhancer in immunocompromised populations. In China, Tα1 has been widely utilized in oncology settings and as an emergency immune modulator during the SARS and COVID-19 pandemics (Liu & Lu, 2023; Dominari et al., 2020).

Within oncology, Tα1 is not tumoricidal in the conventional sense. Rather, it functions as a biological response modifier (BRM) that reorients the immune system toward anti-tumor competence. The convergence of aging thymic function, treatment-induced immunosuppression, and immune-evasive tumor biology creates a compelling rationale for Tα1 as an adjunctive agent across multiple phases of cancer care. This review synthesizes the current peer-reviewed evidence, with citations drawn exclusively from PubMed-indexed literature.

2. Biochemistry and Pharmacology

Tα1 is an acetylated 28-amino acid peptide (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn) with a molecular weight of approximately 3,108 Da. It is derived through post-translational processing of prothymosin-α and is produced constitutively by thymic epithelial cells, with measurable circulating levels declining with age in parallel with thymic involution. The standard subcutaneous dose used in clinical trials is 1.6 mg administered twice weekly, though some protocols utilize higher or loading doses (Garaci et al., 2015).

Tα1 exhibits high thermal and chemical stability relative to many peptide biologics, contributing to its favorable clinical handling profile. Its biological half-life in vivo is approximately 2 hours following subcutaneous administration, though immunological effects persist well beyond this window due to downstream signaling cascades. Unlike cytokines or monoclonal antibodies, Tα1 does not engage a single defined receptor but rather exerts pleiotropic effects through toll-like receptor (TLR) signaling—particularly TLR2 and TLR9—as well as through modulation of transcription factors including NF-κB and STAT signaling pathways (Liu & Lu, 2023).

3. Mechanisms of Action in Tumor Immunology

3.1 Enhancement of T-Cell Function

Central to the anti-tumor activity of Tα1 is its capacity to restore and amplify T-lymphocyte function. Within the tumor microenvironment, chronic antigen exposure leads to T-cell exhaustion, characterized by upregulation of inhibitory receptors such as PD-1, TIM-3, and LAG-3, and reduced cytokine production. Tα1 has been demonstrated to enhance CD4+ T-helper cell differentiation, augment CD8+ cytotoxic T-lymphocyte (CTL) activity, increase interferon-gamma (IFN-γ) production, and reduce markers of T-cell exhaustion (Solmonese et al., 2025).

In a 2025 study by Solmonese and colleagues from the Center for Immuno-Oncology at the University Hospital of Siena, transcriptomic analysis across multiple cancer cell lines and healthy donor immune cell subsets demonstrated that Tα1 exerted its most significant transcriptional impact on activated CD8+ T-cell populations—the principal effectors of tumor cell killing. The study further documented differential effects on CD4+ T cells, B cells, and natural killer (NK) cells, underscoring the peptide’s broad immunomodulatory reach (Solmonese et al., 2025).

3.2 Dendritic Cell Maturation and Antigen Presentation

Dendritic cells (DCs) represent the critical interface between innate and adaptive immunity. Tumor-induced impairment of DC maturation and antigen-presenting function is a principal mechanism by which malignancies evade immune surveillance. Tα1 has been shown to activate DCs via TLR signaling, promoting upregulation of MHC class II molecules and co-stimulatory markers including CD80 and CD86. This DC maturation cascade enhances antigen cross-presentation and promotes differentiation of naïve CD4+ T cells toward Th1 effector phenotypes—a prerequisite for productive anti-tumor cytotoxicity (Liu & Lu, 2023; Garaci et al., 2015).

3.3 Reversal of M2 Macrophage Polarization

Tumor-associated macrophages (TAMs) in the immunosuppressive TME predominantly adopt an M2 (alternatively activated) phenotype, secreting anti-inflammatory cytokines including IL-10 and TGF-β, promoting angiogenesis, and facilitating tumor invasion. In a mechanistically significant 2022 study published in Cancer Research, Liu and colleagues demonstrated that Tα1 reverses M2 macrophage polarization induced by efferocytosis—the phagocytic clearance of apoptotic tumor cells—via activation of the TLR7/SHIP1 signaling axis. By redirecting TAMs toward an M1 pro-inflammatory phenotype, Tα1 effectively converts immunologically “cold” tumors lacking lymphocyte infiltration toward a “hot” tumor phenotype more amenable to checkpoint inhibitor therapy (Liu et al., 2022).

3.4 Suppression of Myeloid-Derived Suppressor Cells

Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of immature myeloid progenitors that accumulate in tumor-bearing hosts and suppress T-cell activity through multiple mechanisms including arginase-1-mediated arginine depletion, nitric oxide production, and reactive oxygen species generation. Elevated MDSC burden is associated with poor response to immunotherapy and shortened survival across multiple cancer types.

Yang and colleagues (2020) demonstrated in both NSCLC patient samples and murine xenograft models that Tα1 blocks MDSC accumulation in the TME primarily through suppression of vascular endothelial growth factor (VEGF) production. Mechanistically, Tα1 promoted apoptosis of monocytic MDSCs (M-MDSCs) by reducing the Bcl-2/BAX ratio and inhibited MDSC migration to the tumor via VEGF pathway suppression (Yang et al., 2020). These findings were corroborated by Shi and colleagues (2024), who confirmed via flow cytometry that thymalfasin treatment significantly reduced the proportion of HLA-DR−CD14−CD33+ MDSCs in peripheral blood and tumor tissue of NSCLC patients (Shi et al., 2024).

3.5 Synergy With Immune Checkpoint Inhibitors

The mechanistic logic for combining Tα1 with ICIs is compelling. Checkpoint inhibitors remove inhibitory “brakes” on T-cell activity, but require a sufficient baseline of functional T cells and adequately primed antigen-presenting cells to generate durable responses. Tα1 addresses upstream deficits in T-cell abundance and DC function that limit ICI efficacy—particularly in cold tumors and patients with treatment-induced lymphopenia.

Preclinical studies have shown that low-dose Tα1, while ineffective as monotherapy, significantly enhanced the anti-tumor efficacy of anti-PD-1 antibodies in a lung metastasis melanoma model. Additionally, Tα1 directly targets NSCLC cells with high PD-L1 expression, blocking proliferation and migration via inhibition of the STAT3-MMP2 signaling pathway, suggesting a potentially complementary mechanism to anti-PD-L1 therapies (Liu & Lu, 2023). Tα1 also appears to confer protection against ICI-related immune adverse events, particularly immune-mediated colitis—an observation with meaningful implications for combination therapy tolerability (Wei et al., 2023).

4. Clinical Evidence by Tumor Type

4.1 Non-Small Cell Lung Cancer

NSCLC represents the most extensively studied oncology indication for Tα1, with evidence spanning resectable early-stage disease through unresectable locally advanced disease treated with concurrent chemoradiotherapy (CCRT).

In the adjuvant setting, Guo and colleagues (2021) conducted a propensity score-matched analysis evaluating the long-term survival impact of Tα1 immunomodulatory therapy following R0 resection in NSCLC patients. The study demonstrated statistically significant improvements in overall survival (OS) in the Tα1-treated cohort compared to matched controls, establishing the biological plausibility of sustained immune enhancement in the perioperative context (Guo et al., 2021).

In locally advanced unresectable NSCLC (stages IIIA–IIIC), a 2025 retrospective analysis by Zhang and colleagues evaluated 196 patients treated with CCRT followed by consolidative immunotherapy, with a subset receiving long-term Tα1 integration. The Tα1-treated group demonstrated superior OS and progression-free survival (PFS) compared to controls. Critically, Tα1 integration was associated with reduced rates of grade ≥2 radiation pneumonitis, accelerated lymphocyte recovery post-CCRT, and suppression of pro-inflammatory interleukin-6 (IL-6). These immunological effects enhanced eligibility for consolidative ICI therapy—a clinically significant finding given that radiation-induced lymphopenia substantially impairs the efficacy of subsequent immunotherapy (Zhang et al., 2025).

A systematic review and meta-analysis by Zeng and colleagues (2019), encompassing 27 randomized controlled trials (RCTs) involving Chinese patients with NSCLC receiving synthetic thymic peptides alongside chemotherapy, demonstrated consistent improvements in immune parameters and quality of life, though the heterogeneity of included interventions limits generalizability (Zeng et al., 2019).

4.2 Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) presents a particularly immunosuppressive tumor microenvironment and frequently develops in the context of viral hepatitis—conditions in which Tα1 has established regulatory approval. The FDA granted Orphan Drug Designation to thymalfasin for both malignant melanoma and HCC, reflecting acknowledged therapeutic potential in these indications.

In the adjuvant post-resection setting, Liang and colleagues (2016) demonstrated in a retrospective controlled study that Tα1 therapy following radical hepatectomy for HBV-associated HCC significantly improved recurrence-free survival (RFS) with a hazard ratio of 0.381 (95% CI: 0.229–0.633; p < .001), representing a clinically and statistically meaningful reduction in recurrence risk (Liang et al., 2016).

In the advanced unresectable setting, a 2025 retrospective study by Yao and colleagues examined 92 patients with unresectable HCC treated with lenvatinib plus sintilimab, with or without Tα1 addition. The Tα1 combination group (n = 43) demonstrated superior median OS (16.0 vs. 11.0 months) and median PFS compared to the dual-agent control group, with objective response rates and disease control rates trending favorably in the experimental arm. No significant increase in treatment-related adverse events was observed (Yao et al., 2025).

4.3 Melanoma

Melanoma was among the first malignancies systematically studied with Tα1, predating the checkpoint inhibitor era. Early randomized trials combining Tα1 with dacarbazine-based regimens in metastatic melanoma demonstrated improved tumor response rates, though overall survival benefits were not consistently demonstrated as primary endpoints in pivotal trials.

In the contemporary checkpoint inhibitor era, Di Giacomo and colleagues (2018) published long-term follow-up data from metastatic melanoma patients who had received Tα1 prior to ipilimumab (anti-CTLA-4). The authors reported a 5-year overall survival rate of 41.2% in patients who received Tα1 preceding checkpoint inhibitor therapy, compared to a historical 5-year OS rate of approximately 13% with ipilimumab monotherapy. While these retrospective findings require prospective validation, they suggest a durable survival benefit potentially attributable to Tα1-mediated immune priming before CTLA-4 blockade (Di Giacomo et al., 2018).

4.4 Breast Cancer

Preclinical mechanistic data support potential Tα1 activity in breast cancer. Guo and colleagues (2015) demonstrated in breast cancer cell lines that Tα1 suppressed tumor cell proliferation and induced apoptosis through PTEN-mediated inhibition of the PI3K/Akt/mTOR signaling pathway—a pathway frequently dysregulated in breast malignancies (Guo et al., 2015). While clinical breast cancer studies remain limited, ongoing investigations of Tα1 in combination with checkpoint inhibitors may include breast cancer cohorts.

4.5 Colorectal Cancer

A prospective randomized controlled trial by Niu and colleagues (2023) evaluated the effects of thymalfasin on perioperative immune function and long-term prognosis in patients undergoing surgery for colorectal cancer. The study found favorable immunological effects in the perioperative period with trends toward improved prognosis in the treated cohort, though confirmatory data from larger trials are awaited (Niu et al., 2023).

5. Thymosin Alpha-1 and Radiotherapy-Immunotherapy Combinations

Radiation therapy exerts a paradoxical dual effect on anti-tumor immunity. While radiotherapy can generate immunogenic cell death and potentially enhance systemic immune responses—including the abscopal effect—it simultaneously induces severe lymphopenia that impairs immunotherapy efficacy. Absolute lymphocyte count (ALC) has emerged as an important predictive biomarker for ICI outcomes; patients with ALC ≤625 cells/μL demonstrate median OS of approximately 6 months compared to 12 months in those with ALC >625 cells/μL (Zhang et al., 2025).

A 2025 study by Shi and colleagues specifically evaluated the effect of a Tα1 loading-dose regimen on peripheral blood lymphocyte reconstitution in patients with advanced or refractory cancers receiving radiotherapy combined with PD-1 inhibitors. The study documented that Tα1 loading doses significantly increased T-cell and T-cell subset counts, providing preliminary evidence that Tα1 can mitigate radiation-induced lymphopenia and thereby enhance the immunological substrate required for effective ICI responses. The authors reported favorable objective response rates and disease control rates alongside an acceptable safety profile in this heavily pretreated population.

A multicenter Phase II study evaluating hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and Tα1 in patients with metastatic solid tumors demonstrated promising systemic immune activation and response rates—consistent with Tα1 enhancing the abscopal immune response generated by focal tumor irradiation (Yu et al., 2025).

6. Safety Profile

One of the most clinically attractive characteristics of Tα1 is its consistently favorable tolerability profile across more than four decades of clinical study. Across hepatitis, sepsis, cancer, and COVID-19 investigations, adverse events have been predominantly mild and include:

• Injection-site reactions (erythema, mild induration)
• Transient fatigue
• Mild flu-like symptoms (myalgia, low-grade fever)
• Rare transient elevations in hepatic enzymes

Notably, Tα1 has not been strongly associated with the severe immune-related adverse events (irAEs)—including immune pneumonitis, colitis, hepatitis, or endocrinopathies—that complicate checkpoint inhibitor therapy. Preclinical evidence from D’Onofrio and colleagues suggests Tα1 may actually protect against CTLA-4-related intestinal immunopathology, potentially reducing colitis risk in combination ICI regimens (as cited in Liu & Lu, 2023). Long-term comprehensive safety data in oncology combination regimens remain incomplete, and post-marketing surveillance in expanded clinical programs will be essential.

7. Integrative Oncology Perspective

At the practice of Yoon Hang Kim, MD, the approach to oncology support begins with a thorough understanding of each patient’s immune functional status, treatment trajectory, and goals of care. Thymosin Alpha-1 represents an illustrative example of how evidence-informed peptide therapy may serve as a rational adjunct—not a replacement—to conventional oncologic treatment.

The profile of patients most likely to benefit from Tα1 integration includes those with:

• Treatment-induced lymphopenia limiting ICI eligibility or efficacy
• Immunosuppressive tumor types (e.g., HCC, cold-tumor NSCLC)
• Post-surgical settings in resectable HCC or NSCLC where immune reconstitution supports adjuvant benefit
• Multimodal regimens combining chemotherapy and radiotherapy where immune preservation is a goal
• Individuals with age-related thymic involution limiting endogenous Tα1 production

It is equally important to recognize what Tα1 is not: it is not a curative intervention, not a substitute for evidence-based oncologic care, and not a therapy to be initiated without proper oncologic coordination. As with all integrative interventions, the discussion must begin with an honest assessment of the current state of evidence, the patient’s individual risk-benefit profile, and seamless communication with the treating oncology team.

8. Limitations of Current Evidence

The accumulating body of Tα1 oncology evidence carries important methodological constraints that must temper clinical interpretation:

8.1 Predominance of Retrospective and Single-Center Data

The majority of positive clinical studies are retrospective, single-center, and limited in sample size. Selection bias, unmeasured confounders, and lack of blinding preclude definitive causal inference from these designs.

8.2 Heterogeneity of Treatment Protocols

Studies vary substantially in Tα1 dosing schedules, tumor type inclusion criteria, comparator regimens, and combination partners. This heterogeneity renders cross-study comparison difficult and precludes meta-analytic synthesis for most cancer-specific endpoints.

8.3 Geographic and Regulatory Variation

The majority of clinical evidence originates from Chinese research centers, where Tα1 has been approved and widely used for decades. Regulatory contexts, supportive care protocols, and underlying patient populations may differ meaningfully from Western clinical settings, limiting direct generalizability.

8.4 Absence of Large Phase III RCT Data in Oncology

No large, multicenter, randomized, placebo-controlled Phase III trial has been completed with OS as the primary endpoint in a modern oncology combination regimen. Ongoing Phase II trials in NSCLC (NCT06139419) will provide more controlled data, though Phase III confirmation remains necessary before Tα1 can be considered a standard component of oncology care.

9. Future Research Directions

The research trajectory for Tα1 in oncology is rapidly evolving. Priority domains for future investigation include:

• Biomarker-guided patient selection: Identifying baseline immune signatures—including ALC, T-cell subset profiles, MDSC burden, and tumor PD-L1 expression—predictive of Tα1 response
• Prospective Phase II/III RCTs in NSCLC, HCC, and gastric cancer with pre-specified immunological and survival endpoints
• Optimal sequencing and dosing: Defining the ideal timing of Tα1 administration relative to ICI initiation, chemotherapy cycles, and radiotherapy fractions
• Prevention and management of ICI toxicities: Characterizing the protective role of Tα1 against immune-related adverse events in combination regimens
• Cellular therapy enhancement: Evaluating Tα1 as a priming agent before CAR-T or NK-cell infusions
• Next-generation formulations: PEGylated Tα1 derivatives and sustained-release formulations aimed at extending half-life and reducing injection frequency

10. Conclusion

Thymosin Alpha-1 occupies a distinctive position in the integrative oncology pharmacopeia: a well-characterized, endogenous immune peptide with decades of safety data, plausible mechanistic rationale, and a growing body of peer-reviewed clinical evidence supporting adjunctive utility across multiple malignancy types. Its capacity to enhance T-cell function, promote dendritic cell maturation, reverse M2 macrophage polarization, suppress MDSCs, and mitigate treatment-induced lymphopenia addresses precisely the immunological vulnerabilities that limit conventional and checkpoint-based cancer therapies.

Current PubMed-indexed evidence supports Tα1 as particularly promising in NSCLC—especially in the context of CCRT and consolidative immunotherapy—and in HCC as adjuvant post-resection therapy and in combination with targeted therapy plus checkpoint inhibitors. Melanoma data suggest durable survival benefits when Tα1 precedes CTLA-4 blockade. Preclinical evidence in breast cancer and clinical signals in colorectal cancer warrant further prospective investigation.

Scientific enthusiasm must be calibrated to evidence integrity. The overwhelming majority of current data is retrospective, geographically concentrated, and methodologically heterogeneous. Large prospective randomized trials are essential before Tα1 integration can be formalized in standard oncology practice guidelines. Nevertheless, the convergence of mechanistic elegance, favorable safety, and clinical signals across diverse tumor types positions Thymosin Alpha-1 as one of the most compelling investigational adjuncts in integrative oncology—a field that increasingly recognizes immune optimization as central to comprehensive cancer care.

References

All references are indexed in PubMed unless otherwise noted. APA 7th Edition format.

1.  Di Giacomo, A. M., Altomonte, M., & Maio, M. (2018). Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: Investigating immune checkpoints synergy. Expert Opinion on Biological Therapy, 18(Suppl. 1), 77–83. https://doi.org/10.1080/14712598.2018.1494717 PMID: 30063847

2.  Dominari, A., Hathaway, D., III, Pandav, K., Manaktala, P., Harberson, J., & Tandel, M. (2020). Thymosin alpha 1: A comprehensive review of the literature. World Journal of Virology, 9(5), 67–78. https://doi.org/10.5501/wjv.v9.i5.67 PMID: 33134175

3.  Garaci, E., Pica, F., Matteucci, C., Gaziano, R., D’Agostini, C., Miele, M. T., … Sinibaldi Vallebona, P. (2015). Historical review on thymosin α1 in oncology: Preclinical and clinical experiences. Expert Opinion on Biological Therapy, 15(Suppl. 1), S31–S39. https://doi.org/10.1517/14712598.2015.1017466 PMID: 26096345

4.  Guo, C. L., Mei, J. D., Jia, Y. L., Gan, F. Y., Tang, Y. D., Liu, C. W., … Liu, L. X. (2021). Impact of thymosin alpha1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: A propensity score-matched analysis. Chinese Medical Journal (English), 134(22), 2700–2709. https://doi.org/10.1097/CM9.0000000000001819 PMID: 34732663

5.  Guo, Y., Chang, H., Li, J., Xu, X. Y., Shen, L., Yu, Z. B., & Liu, W. C. (2015). Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway. Apoptosis, 20(8), 1109–1121. https://doi.org/10.1007/s10495-015-1138-9 PMID: 26002438

6.  Liang, Y. R., Guo, Z., Jiang, J. H., Xiang, B. D., & Li, L. Q. (2016). Thymosin α1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study. Oncology Letters, 12(5), 3513–3518. https://doi.org/10.3892/ol.2016.5121 PMID: 27900029

7.  Liu, X., Cao, F., Mou, Y., Mo, X., Zhang, Y., Chen, J., … Zou, Z. (2022). Thymosin α-1 reverses M2 polarization of tumor-associated macrophages during efferocytosis. Cancer Research, 82(11), 1991–2002. https://doi.org/10.1158/0008-5472.CAN-21-2776

8.  Liu, Y., & Lu, J. (2023). Mechanism and clinical application of thymosin in the treatment of lung cancer. Frontiers in Immunology, 14, 1237978. https://doi.org/10.3389/fimmu.2023.1237978 PMID: 37701432

9.  Niu, W., Li, Z., & Li, Z. (2023). A prospective and randomized control study on effects of thymalfasin for injection on perioperative immune function and long-term prognosis of patients with colorectal cancer. Biotechnology & Genetic Engineering Reviews. https://doi.org/10.1080/02648725.2023.2211337

10.  Shi, F., Qiu, H., Yan, J., Ke, C., & Li, Y. (2024). Effect of thymalfasin on myeloid-derived suppressor cells in patients with non-small cell lung cancer. American Journal of Translational Research, 16(5), 1790–1797. https://doi.org/10.62347/QSWS7848 PMID: 38883367

11.  Solmonese, L., Lofiego, M. F., Fazio, C., Marzani, F., Piazzini, F., Bello, E., … Covre, A. (2025). The immunomodulatory activity of Thymosin Alpha 1 on tumor cell lines and distinct immune cell subsets. OncoTargets and Therapy, 18, 995–1012. https://doi.org/10.2147/OTT.S527785 PMID: 40955371

12.  Wei, Y., Zhang, Y., Li, P., Li, J., Zhang, Y., Zhang, Y., … Chen, G. (2023). Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. International Immunopharmacology, 117, 109744. https://doi.org/10.1016/j.intimp.2023.109744

13.  Yang, Z., Guo, J., Cui, K., Wan, M., Su, M., Zhao, Q., … Chen, G. (2020). Thymosin alpha-1 blocks the accumulation of myeloid suppressor cells in NSCLC by inhibiting VEGF production. Biomedicine & Pharmacotherapy, 131, 110740. https://doi.org/10.1016/j.biopha.2020.110740 PMID: 32942159

14.  Yao, S., Huang, Q., Zou, Y., Chen, G., … Huang, Q. (2025). The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: A retrospective study. Scientific Reports, 15, 13960. https://doi.org/10.1038/s41598-025-97160-7

15.  Yu, J., Xia, Y., Chen, Z., Zhang, X., Zeng, Y., Li, J., … Liu, H. (2025). Hypofractionated radiotherapy combined with a PD-1 inhibitor, GM-CSF, and thymosin α1 in metastatic solid tumors. PubMed Central (PMC11794727). Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-03967-8

16.  Zeng, F. L., Xiao, Z., Wang, C. Q., Bian, X. Q., Tang, X. H., & Lv, F. F. (2019). Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: A systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines. International Immunopharmacology, 75, 105747. https://doi.org/10.1016/j.intimp.2019.105747

17.  Zhang, H. T., Liu, F. J., Wang, D. Q., Xiong, Y. X., Zhao, Y. Y., He, W. Z., … Liu, H. (2025). A preliminary analysis of integrating thymosin α1 into concurrent chemoradiotherapy and consolidative immunotherapy in unresectable locally advanced non-small cell lung cancer. Translational Lung Cancer Research, 14(7), 2710–2722. https://doi.org/10.21037/tlcr-2025-190 PMID: 40799433

© 2025 The Practice of Yoon Hang Kim, MD | Yoon Hang Kim, MD, MPH | All rights reserved. Reproduction without permission is prohibited.